Condensation of 5,6-dihydroindolo[2,1-a]isoquinoline with aromatic aldehydes in trifluoroacetic acid afforded 12-arylidene-5,6-dihydroindolo[2,1-a]isoquinolinium trifluoroacetates. Hydrogenolysis of these salts on rhenium heptasulfide at elevated temperature and hydrogen pressure yielded indolo[2,1-a]isoquinolines, while reduction with sodium borohydride gave 12-arylmethylindoloisoquinolines. Photoluminescence was found for some indolo[2,1-a]isoquinolines.
Ruthenium‐catalyzedcycloisomerization of 2‐ethynylbiaryls was investigated to identify an optimal ruthenium catalyst system. A combination of [η6‐(p‐cymene)RuCl2(PR3)] and two equivalents of AgPF6 effectively converted 2‐ethynylbiphenyls into phenanthrenes in chlorobenzene at 120 °C over 20 h. Moreover, 2‐ethynylheterobiaryls were found to be favorable substrates for this ruthenium catalysis, thus
A concise synthesis of indolo[2,1-a]isoquinoline via alkyne annulations promoted by base
作者:Hina Mehmood、Muhammad Asif Iqbal、Ruimao Hua
DOI:10.1016/j.tetlet.2021.153566
日期:2022.1
A convenient and one-pot synthetic method for the construction of indolo[2,1-a]isoquinolines is developed by the dehydrative cyclocondensation reactions of the easily available 2-hydroxymethyl anilines with 2-ethynylbenzaldehydes in DMSO in the presence of KOH and TBAI under air.
Synthesis of Phenanthrenes and Polycyclic Heteroarenes by Transition-Metal Catalyzed Cycloisomerization Reactions
作者:Victor Mamane、Peter Hannen、Alois Fürstner
DOI:10.1002/chem.200400220
日期:2004.9.20
Readily available biphenyl derivatives containing an alkyne unit at one of their ortho-positions are converted into substituted phenanthrenes on exposure to catalytic amounts of either PtCl2, AuCl, AuCl3, GaCl3 or InCl3 in toluene. This 6-endo-dig cyclization likely proceeds through initial pi-complexation of the alkyne unit followed by interception of the resulting eta2-metal species by the adjacent
Preventives and remedies for central nervous system diseases
申请人:——
公开号:US20030207863A1
公开(公告)日:2003-11-06
A prophylactic or therapeutic agent for central nervous system diseases based on amyloid &bgr;40 secretion inhibitory activity of a compound having urotensin II receptor antagonistic activity or a salt thereof.
Preventives/remedies for voiding disturbance containing a compound having both of an acetylcholinesterase inhibitory action and an α1 antagonistic action which exhibits an excellent effect of improving the urinary function of the bladder (i.e., effects of improving urine flow rate and voiding efficiency) without affecting the urinary pressure or the blood pressure.